However, in the PLATO study (A Comparison of Ticagrelor [AZD6140] and Clopidogrel in Patients With Acute Coronary Syndrome) [2], pretreatment with the assigned P2Y12 inhibitor was mandatory per-protocol, and ticagrelor was associated with an early benefit over clopidogrel in invasively managed NSTE-ACS patients irrespective of the timing of angiography [9]. This evidence concerns the gene P2RY12 and acute coronary syndrome.